ELEV20260116C2.5
ELEV Jan 16 2026 2.50 Call (ELEV260116C00002500)
option OPRA

elevation oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. we make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. our lead candidate, seribantumab, inhibits tumor growth driven by nrg1 fusions and is currently being clinically tested in the phase 2 crestone study for patients with tumors of any origin that have an nrg1 fusion. learn more about crestone at www.nrg1fusion.com. elevation oncology is backed by aisling capital, vertex ventures hc, qiming venture partners usa, driehaus capital management, and bvf partners.